Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in mye… Read more
Market Cap & Net Worth: Aptose Biosciences Inc (APTO)
Aptose Biosciences Inc (NASDAQ:APTO) has a market capitalization of $5.13 Million ($5.13 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #36055 globally and #11729 in its home market, demonstrating a -42.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptose Biosciences Inc's stock price $2.01 by its total outstanding shares 2552430 (2.55 Million).
Aptose Biosciences Inc Market Cap History: 2015 to 2025
Aptose Biosciences Inc's market capitalization history from 2015 to 2025. Data shows change from $96.86 Million to $5.13 Million (-30.14% CAGR).
Index Memberships
Aptose Biosciences Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #895 of 976 |
Weight: Aptose Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptose Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptose Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APTO by Market Capitalization
Companies near Aptose Biosciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Aptose Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aptose Biosciences Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Aptose Biosciences Inc's market cap moved from $96.86 Million to $ 5.13 Million, with a yearly change of -30.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.13 Million | +792.14% |
| 2024 | $575.06K | -91.13% |
| 2023 | $6.48 Million | -70.80% |
| 2022 | $22.21 Million | -57.04% |
| 2021 | $51.69 Million | -69.18% |
| 2020 | $167.69 Million | -22.75% |
| 2019 | $217.08 Million | +196.86% |
| 2018 | $73.13 Million | -14.73% |
| 2017 | $85.76 Million | +61.15% |
| 2016 | $53.22 Million | -45.06% |
| 2015 | $96.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aptose Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.13 Million USD |
| MoneyControl | $5.13 Million USD |
| MarketWatch | $5.13 Million USD |
| marketcap.company | $5.13 Million USD |
| Reuters | $5.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.